Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial
van der Heijde, Désirée, Baraliakos, Xenofon, Gensler, Lianne S, Maksymowych, Walter P, Tseluyko, Vira, Nadashkevich, Oleg, Abi-Saab, Walid, Tasset, Chantal, Meuleners, Luc, Besuyen, Robin, Hendrikx,Language:
english
Journal:
The Lancet
DOI:
10.1016/S0140-6736(18)32463-2
Date:
October, 2018
File:
PDF, 709 KB
english, 2018